Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
PeptidesDBan atlas
← CataloguePlate 80 of 81
80Plate 80Reviewed 2026-04-27

Vilon

Khavinson Bioregulator

also known as Lys-Glu, KE

Dipeptide (Lys-Glu) from the Khavinson bioregulator school. Smallest Khavinson peptide. Animal models demonstrate immune cell differentiation induction, thymocyte proliferation enhancement, and potential lifespan extension. Proposed mechanism: epigenetic modulation via gene expression suppression (CCL11, HMGB1) in aging chromatin. Clinical evidence absent; Russian gerontological literature dominant.

§ I

At a glance

Dipeptide
2 AA
Stimulates
T-helper
[linkova-2011]
Model basis
Mouse
[khavinson-2002]
Route

Literature lacks standardised clinical route

§ II

Mechanism

Edit ↗

Primary target — Immune cell differentiation pathways, chromatin modification.

Pathway — Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1).

Downstream effect — Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytes [linkova-2011][khavinson-2002][lezhava-2023].

Origin — Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction) [morozov-1997].

Feedback intact — Unknown — no HPA/HPG axis data.

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Standard doseNo clinical standard — literature lacks human dosingRussian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model doseIn vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)Not translatable to human mg/kg without pharmacokinetic data.
FrequencyUnknown — literature does not specify chronic administration protocols
Evidence basisMouse / in vitro only
DurationNot characterised in humans
RouteLikely SQ or oral (Khavinson school uses both); no published ROA validation
Half-lifeNot published — dipeptides typically <10 min plasma t½
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
mg
mL
mcg
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Vilon's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
≈ 10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose

Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.

§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Human safety datamoderate
Absent from PubMed-indexed literature
Theoretical riskmoderate
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formationmild
Not reported; dipeptides generally low immunogenicity
Animal modelsmild
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute contraindications
  • — Active autoimmune disease (theoretical — no clinical data)
Relative contraindications
  • — Pregnancy / lactation (no safety data)
  • — Acute infection with cytokine storm risk (immune modulation unknown)
§ VI

Administration

Edit ↗
  1. 01
    Dosing uncertainty

    No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

  2. 02
    Theoretical route

    Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

  3. 03
    Timing

    Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

  4. 04
    Storage

    Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

§ VII

Synergies

Edit ↗
moderate synergy
Deterministic 12-node hex coat-of-arms fingerprint for Vilon, generated from the slug hash. Decorative; the same slug always produces the same motif.+Deterministic 12-node hex coat-of-arms fingerprint for Epitalon, generated from the slug hash. Decorative; the same slug always produces the same motif.
Vilon + Epitalon

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Primary benefit — Multi-system aging modulation (immune + pineal/circadian)
weak synergy
Deterministic 12-node hex coat-of-arms fingerprint for Vilon, generated from the slug hash. Decorative; the same slug always produces the same motif.+Deterministic 12-node hex coat-of-arms fingerprint for Thymalin, generated from the slug hash. Decorative; the same slug always produces the same motif.
Vilon + Thymalin

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Primary benefit — Redundant — both target T-cell differentiation
Appendix

Sources

27%

of 49 rendered claims carry a resolvable citation.

  1. [khavinson-2002]
    Khavinson 2002 — Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway.
    journal, 2002
    PubMed →
  2. [khavinson-2014]
    Khavinson 2014 — [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data].
    journal, 2014
    PubMed →
  3. [khavinson-2020]
    Khavinson 2020 — Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.
    journal, 2020
    PubMed →
  4. [lezhava-2023]
    Lezhava 2023 — EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
    journal, 2023
    PubMed →
  5. [linkova-2011]
    Linkova 2011 — Peptidegic stimulation of differentiation of pineal immune cells.
    journal, 2011
    PubMed →
  6. [morozov-1997]
    Morozov 1997 — Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
    journal, 1997
    PubMed →
Plate composed 2026-04-27 · maturity human-reviewed · schema v1 · Contributors: peptidesdb-core · 36 fields uncited — open contributions
Edit on GitHub →Suggest a citation →All contributors ↗Read another →